Baxter Buys Gambro For $4 Billion To Round Out Dialysis Device Lineup
This article was originally published in The Gray Sheet
Deal builds on Baxter’s home peritoneal dialysis-focused business by adding a suite of products for hemodialysis in the clinic, including Gambro’s Artis and AK 96 systems.
You may also be interested in...
NxStage’s System One has received an expanded indication to treat patients overnight at home, which the company says improves quality of life.
Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.
Propelled by the completion of two large acquisitions, the previous quarter was a strong one for device industry M&A activity, and indicators suggest the deal making will continue, PricewaterhouseCoopers says.